荧光定量PCR技术在肿瘤研究中的应用

被引:6
作者
陈文学
陈岳青
黄秀珍
机构
[1] 江西省肿瘤医院
[2] 江西省肿瘤医院 南昌市
[3] 南昌市
关键词
FQ-PCR; 肿瘤; 多药耐药基因;
D O I
暂无
中图分类号
R73-3 [肿瘤学实验研究];
学科分类号
100214 ;
摘要
荧光定量PCR技术具有简便、灵敏、准确等优点 ,目前已经在乙肝和性病的诊断和治疗中得到了广泛的应用 ,但是在肿瘤中的应用还处在研究和开发阶段 ,本文综述国内外近几年应用荧光定量PCR技术在肿瘤研究中的应用。
引用
收藏
页码:323 / 326
页数:4
相关论文
共 19 条
[1]  
Measurements of human papillomavirus transcripts by real time quantitative reverse transcription-polymerase chain reaction in samples collected for cervical cancer screening. Lamarcq L,Deeds J,Ginzinger D,et al. The Journal of Molecular Diagnostics . 2002
[2]  
Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. DONG SM,PAI SI,RHA SH,et al. Cancer Epidemiology Biomarkers and Prevention . 2002
[3]  
Leukemia[P]. 英国专利:GB0221802D0,2002-10-30
[4]  
Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Chuma M,Sakamoto M,Yamazaki K,et al. Hepatology . 2003
[5]  
Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Reis PP,Rogatto SR,Kowalski LP et al. Oncegene . 2002
[6]  
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Weigelt B,Bosma AJ,Hart AA,et al. British Journal of Cancer . 2003
[7]  
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Sfiligoi C,de Luca A,Cascone I. International Journal of Cancer . 2003
[8]  
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2,and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Burger H,Foekens JA,Look MP,et al. Clinical Cancer Research . 2003
[9]  
Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. Dong SM,Pai SI,Rha SH,et al. Journal of the National Cancer Institute . 2002
[10]  
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP,Kaeda J,Branford S,et al. The New England Journal of Medicine . 2003